Compare GOODO & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Current Price
| Metric | GOODO | RVPHW |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 72 | 14 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | GOODO | RVPHW |
|---|---|---|
| Price | $20.78 | $0.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 22.4K |
| Earning Date | N/A | 03-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $0.13 |
| 52 Week High | N/A | $0.15 |
| Indicator | GOODO | RVPHW |
|---|---|---|
| Relative Strength Index (RSI) | 68.18 | 23.38 |
| Support Level | $20.20 | $0.01 |
| Resistance Level | $20.68 | $0.01 |
| Average True Range (ATR) | 0.20 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 86.36 | 0.00 |
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.